Proactive Investors - Run By Investors For Investors

genedrive shares push higher as the rapid diagnostics specialist gears up for important year

In an update on trading, chief executive David Budd said he was pleased with the progress
genedrive shares push higher as the rapid diagnostics specialist gears up for important year
Revenues were in line with market forecasts
genedrive plc (LON:GDR) saw its shares jump 5% higher on Friday as the rapid diagnostics specialist said it is applying for an additional £2mln of grant funding as it updated on current trading.
 
The awards will be used to progress work on the company's hepatitis-c and tuberculosis products.

WATCH: Genedrive receives NHS grant to develop and implement point-of-care test

In the year ended June 30, the business generated sales of £1.9mln, which while lower than the comparable period last year, were in line with market expectations and reflected the completion of an order for the US Department of Defence. genedrive ended the period with cash of £3.5mln.
 
In February, it made its first commercial shipments of the Genedrive HCV ID Kit (for diagnosing hepatitis-c) and further commercial sales have followed. 
 
The company said was applying for around 30 import licences as its commercial efforts ramp up.
 
"In conjunction with our distributors, we took the decision to hold back product registrations so we could include new extended product stability claims," genedrive told investors. 
 
"These improved performance claims will assist future commercialisation efforts and we envisage the majority of registration dossiers being submitted during the next month." 
 
Chief executive David Budd said he was pleased with the progress.
 
In late morning trading, genedrive shares were 5.2% higher at 30.5p.
 
 -- Adds share price --
 
View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
researcher at microscope
Fri
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use